Literature DB >> 33012623

Variations in Hepatitis B Vaccine Series Completion by Setting Among Adults at Risk in West Virginia.

Stacy Tressler1, Christa Lilly2, Diane Gross3, Thomas Hulsey4, Judith Feinberg5.   

Abstract

INTRODUCTION: West Virginia leads the nation with the highest rate of acute hepatitis B. From 2013 to 2015, the West Virginia hepatitis B Vaccination Pilot Project distributed more than 10,000 doses of hepatitis B vaccine to at-risk adults through local health department clinics and through outreach to correctional facilities and substance use treatment centers. This study aims to determine which setting type is associated with the greatest likelihood of at-risk adults receiving all 3 or at least 2 doses of hepatitis B vaccine.
METHODS: Data for this retrospective cohort study were accessed, extracted, and analyzed in 2019 from Pilot Project participant forms initially completed from 2013 to 2015. Odds of receiving all 3 or at least 2 doses were calculated using bivariate, multivariable, and mixed-effects regression models.
RESULTS: Data were available for 1,201 participants. In multivariable logistic regression, participants vaccinated at substance use treatment centers (AOR=1.37, 95% CI=1.01, 1.86) and local health department family planning clinics (AOR=3.74, 95% CI=1.98, 7.06) were more likely to receive the 3-dose series versus those vaccinated at local health department sexually transmitted disease clinics. Participants vaccinated through substance use treatment centers (AOR=1.79, 95% CI=1.31, 2.44), correctional facilities (AOR=3.34, 95% CI=2.09, 5.34), and local health department family planning clinics (AOR=3.97, 95% CI=1.72, 9.16) were more likely to receive at least 2 doses.
CONCLUSIONS: Hepatitis B vaccination delivered at local health department family planning clinics, substance use treatment centers, or correctional facilities may increase vaccine dose completion in West Virginia.
Copyright © 2020 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33012623      PMCID: PMC7988884          DOI: 10.1016/j.amepre.2020.05.022

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  8 in total

1.  Overview of clinical studies with hepatitis B vaccine made by recombinant DNA.

Authors:  B A Zajac; D J West; W J McAleer; E M Scolnick
Journal:  J Infect       Date:  1986-07       Impact factor: 6.072

2.  A Two-Dose Hepatitis B Vaccine for Adults (Heplisav-B).

Authors: 
Journal:  JAMA       Date:  2018-02-27       Impact factor: 56.272

3.  A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults.

Authors:  Eric E Mast; Cindy M Weinbaum; Anthony E Fiore; Miriam J Alter; Beth P Bell; Lyn Finelli; Lance E Rodewald; John M Douglas; Robert S Janssen; John W Ward
Journal:  MMWR Recomm Rep       Date:  2006-12-08

4.  Trends in Hepatitis B Infection and Immunity Among Women of Childbearing Age in the United States.

Authors:  Tatyana Kushner; Zhen Chen; Stacy Tressler; Harvey Kaufman; Judith Feinberg; Norah A Terrault
Journal:  Clin Infect Dis       Date:  2020-07-27       Impact factor: 9.079

5.  Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine.

Authors:  F E André
Journal:  Am J Med       Date:  1989-09-04       Impact factor: 4.965

6.  Increases in Acute Hepatitis B Virus Infections - Kentucky, Tennessee, and West Virginia, 2006-2013.

Authors:  Aaron M Harris; Kashif Iqbal; Sarah Schillie; James Britton; Marion A Kainer; Stacy Tressler; Claudia Vellozzi
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-01-29       Impact factor: 17.586

7.  Challenges with hepatitis B vaccination of high risk adults - A pilot program.

Authors:  Carolyn B Bridges; Tureka L Watson; Noele P Nelson; Maribel Chavez-Torres; Patrick Fineis; Boatemaa Ntiri-Reid; Edward Wake; Judith M Leahy; Anita K Kurian; Mary Ann K Hall; Erin D Kennedy
Journal:  Vaccine       Date:  2019-07-11       Impact factor: 3.641

8.  Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant.

Authors:  Sarah Schillie; Aaron Harris; Ruth Link-Gelles; José Romero; John Ward; Noele Nelson
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-04-20       Impact factor: 17.586

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.